- Delen: Home
- ...
- Terminology & Classifications News
Terminology & Classifications News
Filtered by SNOMED CT Remove tag search
-
Changes to dm+d and SNOMED CT UK Drug Extension - Status update
Published: May 2023
Dear colleague,
Shift to use of UK extension IDs for all VMP concepts in both dm+d and SNOMED CT UK Drug Extension
The changes for the shift to use UK extension IDs for all VMP concepts in both dm+d and SNOMED CT UK Drug Extension are now being made and are available in TRUD. The roll out plan of batches and list of concepts affected by these changes are available here. Please always refer to this webpage for the latest information on the changes taking place. Further information about the above changes and the others planned for later in 2023 is available at the UK Medicines Terminology Futures pages. If you have any queries relating to any of the changes, please contact the delivery team at nhsdigital.ukmeds@nhs.net
VMP ‘<Drug Form>’ coded attribute in dm+d – your thoughts and views are needed please
The Pharmacy Terminology team continue to seek feedback from dm+d users to understand if and how you use the VMP ‘<Drug_Form>’ coded attribute within the VMP concept class. We are undertaking a piece of discovery work as part of UK Medicines Terminology Futures. Please help by responding to this very short survey. The survey should only take a few minutes to complete and your feedback is invaluable to us so we would be very grateful if you are able to respond. Please be assured that any personal details you submit will be treated in strict confidence.
Thank you in advance and if you have any questions about completing this survey, please contact: nhsdigital.ukmeds@nhs.net. For further information about this change, please visit: Updating the NHS dm+d ‘<DRUG_FORM>’ coded attribute within the Virtual Medicinal Product concept class - NHS Digital
Kind regards,
Terminology and Classifications Delivery Service
By Katy Park 4 weeks ago
-
Notification of possible delay to the SNOMED CT UK Edition Clinical reference sets
Published: March 2023
Dear colleague,
Please be aware that we are currently experiencing a delay to the production of the SNOMED CT UK Edition clinical reference sets (refsets).
This delay may affect the update of the Clinical refsets for the 36.0.0_20230412, due for release on 19 April 2023.
The releases that may be affected are the:
- SNOMED CT UK Clinical Edition, RF2: Delta
- SNOMED CT UK Clinical Edition, RF2: Full, Snapshot & Delta
- SNOMED CT UK Monolith Edition, RF2: Snapshot
- SNOMED CT human-readable subset - UK Clinical Extension
Refsets published as part of the SNOMED CT UK Drug Extension and the SNOMED CT UK Pathology Extension are not affected.
We will send a further update by 5pm on 4 April 2023.
Kind regards
Terminology and Classifications Delivery Service
By Katy Park 2 months ago
-
Shift to use of UK extension IDs for all VMP concepts in both dm+d and SNOMED CT UK Drug Extension - Sample batch 27 February 2023
Published: February 2023
Dear colleague,
The sample batch of 18 VMPs, that are part of the shift to use of UK extension IDs for all VMP concepts in both dm+d and SNOMED CT UK Drug Extension, are now available to download via the Technology Reference Update Distribution (TRUD) website.
The bulk of the VMP ID changes will then proceed from May 2023 onwards. The roll out plan and list of concepts affected by these changes are available on our webiste..
Further information about the above changes and the others planned for later in 2023 is available on the UK Medicines Terminology Futures pages.
If you have any queries about the changes that are taking place, please contact nhsdigital.ukmeds@nhs.net
Kind regards,
Terminology and Classifications Delivery Service
By Katy Park 3 months ago
-
Changes to dm+d and SNOMED CT UK Drug Extension in 2023
Published: December 2022
Dear colleague,
To improve the alignment between dm+d and SNOMED CT UK Drug Extension, in terms of content and release cycles, several changes are taking place to both terminologies in 2023.
To see further details about these changes, please see the UK Medicines Terminology Futures web content. Please bookmark this page and regularly review the content as proposed delivery dates are subject to change.
If you have any specific queries about the changes, email nhsdigital.ukmeds@nhs.net
Kind regards,
Terminology & Classifications Delivery Service
By Katy Park 5 months ago
-
Delay to the release of the 34.0.0 SNOMED CT UK Edition
Published: June 2022
Dear colleague,
Please note that due to the integration of the new SNOMED CT International release and additional requirements to support the Monkeypox outbreak there has been a delay to the production of the 34.0.0 SNOMED CT UK Edition.
This will delay the release of the:
- SNOMED CT International Edition
- SNOMED CT UK Clinical Extension (including the SNOMED CT to ICD-10 and OPCS-4.9 maps)
- SNOMED CT UK Drug Extension
- SNOMED CT UK Pathology Extension
The 34.0.0 SNOMED CT UK Edition will now be published on Friday 22 July 2022, instead of its planned release date of Wednesday 13 July 2022.
NHS Digital is sorry for any inconvenience that this will cause you.
Kind regards
Terminology and Classifications Delivery Service
By Katy Park 11 months ago
-
Notification of SNOMED CT UK Clinical Edition MICRO release 03-Nov-2021
NHS Digital intend to release an unscheduled SNOMED CT UK Clinical Edition MICRO release on 03-Nov-2021.
This release is to support urgent COVID-19 pandemic requirements. The release contains 3 additional concepts.
- Application for medical exemption from COVID-19 vaccination approved
- Application for medical exemption from COVID-19 vaccination rejected
- VITT - vaccine-induced immune thrombotic thrombocytopenia
The release will be available on TRUD as normal and will have a Release ID of 32.6.0 with an Effective Time of 27-Oct-2021.
Further information on the content of this release will be made available at the point of release.
Kind regards,
Terminology and Classifications Delivery Service
By Claire Fennell 1 year ago
-
Changes to 2021/22 SNOMED CT and NICIP releases
Published June 2021
Dear Colleague,
After a review of our Terminology Service we’ve introduced some changes to 2021/22 SNOMED CT UK Clinical Edition and National Interim Clinical Imaging Procedure (NICIP) releases.
Please find more information here
Kind regards,
Terminology and Classifications Delivery Service.
By Claire Fennell 1 year ago
-
COVID-19 Vaccination Codes
Published March 2021
Dear Colleague,
1324761000000100
Document Change Log
Date
Version
Description
13/11/2020
1.0
FINAL document approved by NHS Digital COVID-19 vaccine programme
Jeremy Rogers
Jo Goulding
Helen Harger
26/11/2020
1.1
Updated dm+d descriptions for ‘Courageous’ – now ‘COVID-19 mRNA Vaccine BNT162b2’
Jo Goulding
07/12/2020
1.2
· embedded hyperlinks to TermBrowser updated (now agnostic of SNOMED release)
· minor typo and other text corrections
· Addition of new pack size for BNT162b2 vaccine to allow GTIN addition (2D datamatrix will be on the outer box of 195vials, not on individual vials)
Jeremy Rogers
Jo Goulding
13/12/2020
1.3
Addition of new dm+d concepts for “Astute” vaccine (Janssen/J&J)
· Additions in dm+d release 14/12/2020
· Due in SNOMED CT Browser February 2021
Jo Goulding
06/01/2021
1.4
Updated descriptions for Project Talent (Oxford/AstraZeneca) vaccine
Addition of GTIN information to new packsizes
Note – new dm+d additions not currently in SNOMED CT. Hyperlinks to be added once information available in SNOMED CT release.
Jo Goulding
20/01/2021
1.5
Addition of new dm+d concepts for ‘Renown’ vaccine (Moderna, Inc)
New VTM for all vaccine products
Note – new dm+d additions not currently in SNOMED CT. Hyperlinks to be added once information available in SNOMED CT release.
Updated descriptions for ‘first dose’ SNOMED CT codes to reflect use in single dose vaccination schedules
Jo Goulding
01/02/2021
1.6
Amendments to Pfizer (‘Courageous’) vaccines:
· Pack size change to 6 dose multidose vials (from 5 dose) Note – no change to product, only change to recommendations for use. Therefore, amended pack size descriptions not new products added.
· Word order update in description to follow pattern from other vaccines
· Supplier change to Pfizer Ltd
Jo Goulding
11/02/2021
1.7
Addition of new dm+d concepts for Valneva vaccine.
Note – new dm+d additions not currently in SNOMED CT. Hyperlinks to be added once information available in SNOMED CT release.
Jo Goulding
19/03/2021
1.8
Addition of new dm+d concepts for Novavax vaccine
Addition of single vial (10 dose) VMPP and AMPP concepts for Moderna vaccines
Note – new dm+d additions not currently in SNOMED CT. Hyperlinks to be added once information available in SNOMED CT release.
Jo Goulding
SNOMED CT codes relating to COVID-19 Vaccination
The following is the list of SNOMED CT procedure and product codes intended to support a mass vaccination campaigns in the UK specifically against COVID-19.
The range and intended use of the codes shown here is similar to that already available for other established mass immunisation campaigns – in particular those for which the primary immunisation schedule also involves more than one vaccine dose administration event.
However, unlike the SNOMED CT codesets available for some other national immunisation programmes, much of the administrative detail relating to a patient’s journey through a call:recall system are not covered. This aspect of running the overall campaign will be carried out by a central system that neither needs nor uses SNOMED CT codes specifically in order to represent (for example) when a patient has been sent an urgent SMS notification advising them of a late change to their next immunisation appointment date. Instead, many of the various patient states that this call-recall engine will be required to reason over will be represented only within that system and by some other non-SNOMED CT means, and does not need to be also shared more widely into other live clinical systems as SNOMED CT codes.
The currently available SNOMED CT expressivity, therefore, aims to cover only the core clinical information about an individual’s immunisation journey that should be shareable with any other clinician for whom an understanding of the patient’s immunisation status could influence subsequent clinical decisions.
Which specific vaccine preparation was used at any specific vaccination event will be co-recorded as a separate dm+d code for the vaccine preparation.
The codeset is presented twice; first the raw list of codes and preferred terms and then again but with each code further accompanied by text clarifying its intended clinical meaning and scope.
Scope
This document only details SNOMED CT content related directly to COVID-19 Vaccination.
It does not cover other SNOMED CT content pertaining to COVID-19 disease, complications, treatment etc. (e.g., 1325161000000102 Post-COVID-19 syndrome)
CODE LIST FOR SARS-CoV-2 VACCINATION
Codes shown in black are already published; those in red are new codes added in the 28 October 2020 release of SNOMED CT UK Edition and subsequent releases.
(Codes are hyperlinked to termbrowser.nhs.uk)See following “list with scope notes” for further explanation.
CLINICAL FINDING
1240601000000108 High priority for SARS-CoV-2 vaccination
1240631000000102 Did not attend SARS-CoV-2 vaccination
1324831000000104 Did not attend for first dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine
1324841000000108 Did not attend for second dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine1324661000000105 Adverse reaction to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine
1324711000000102 Allergy to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccinePROCEDURE
1324671000000103 Immunisation course to achieve immunity against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)
1324681000000101 Administration of first dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine
1324691000000104 Administration of second dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccineSITUATION WITH EXPLICIT CONTEXT
1324731000000105 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course not indicated
1324761000000100 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course contraindicated
1324811000000107 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course declined
1324821000000101 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course not done
1324851000000106 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course started
1324861000000109 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course abandoned
1324721000000108 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination dose declined
1324741000000101 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination first dose declined
1324751000000103 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination second dose declined
1324771000000107 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination dose not given
1324781000000109 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination first dose not given
1324791000000106 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination second dose not givenPHARMACEUTICAL / BIOLOGIC PRODUCT
All COVID-19 Vaccine VMPs linked to:
VTM: 39330711000001103 COVID-19 vaccine
Project Courageous (Pfizer):
VMP: 39116111000001100 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials
AMP: 39115611000001103 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd)VMPP: 39115311000001108 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials 6 dose
VMPP: 39214411000001100 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials 1170 dose – 195 x 6 dose vials
AMPP: 39115711000001107 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd) 6 dose
AMPP: 39214511000001101 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd) 1170 dose – 195 x 6 dose vials GTIN: 00359267100023
Project Talent (AstraZeneca):
VMP: 39116211000001106 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials
AMP: 39114911000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca)
VMPP: 39114711000001108 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 8 dose
VMPP: 39114811000001100 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 10 doseVMPP: 39301011000001100 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 80 dose 10 x 8 dose vials
VMPP: 39301111000001104 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 100 dose 10 x 10 dose vialsAMPP: 39115011000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 8 dose
AMPP: 39115111000001106 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 10 doseAMPP: 39301211000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 80 dose 10 x 8 dose vials GTIN: 05000456063876
AMPP: 39301311000001102 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 100 dose 10 x 10 dose vials GTIN: 05000456063821Project Astute (Janssen-Cilag):
VMP: 39233911000001100 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials
AMP: 39230211000001104 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials (Janssen-Cilag Ltd)
VMPP: 39230011000001109 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials 5 dose
VMPP: 39230111000001105 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials 50 dose
AMPP: 39230311000001107 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials (Janssen-Cilag Ltd) 5 dose
AMPP: 39230411000001100 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials (Janssen-Cilag Ltd) 50 doseProject Renown (Moderna):
VMP: 39326811000001106 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5mL dose dispersion for injection multidose vials
AMP: 39326911000001101 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5mL dose dispersion for injection multidose vials (Moderna, Inc)
VMPP: 39375311000001106 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials 10 doseVMPP: 39326611000001107 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials 100 dose 10 x 10 dose vials
AMPP: 39375411000001104 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials (Moderna, Inc) 10 dose
AMPP: 39327011000001102 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials (Moderna, Inc) 100 dose 10 x 10 dose vials GTIN: 30380777700688
Valneva:
VMP: 39375211000001103 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials
AMP: 39373511000001104 COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd)
VMPP: 39373011000001107 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials 10 doseVMPP: 39373111000001108 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials 100 dose 10 x 10 dose vials
AMPP: 39374411000001100 COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd) 10 doseAMPP: 39374711000001106 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd) 100 dose 10 x 10 dose vials GTIN: 09120040710330
Novavax:VMP: 39330711000001103 Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials
VMPP: 39472811000001101 Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials 10 dose
VMPP: 39472911000001106 Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials 100 dose 10 x 10 dose vials
AMP: 39473011000001103 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH)
AMPP: 39473111000001102 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH) 10 dose
AMPP: 39473211000001108 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH) 100 dose 10 x 10 dose vials GTIN: 00380631100103
END.
CODE LIST FOR SARS-CoV-2 VACCINATION, WITH SCOPE NOTES
Codes shown in black are already published; those in red are proposed new codes.
Codes in brown are published but now unlikely to be used.
Codes in grey are published but now inactive and should never be used.CLINICAL FINDING
1240601000000108 High priority for SARS-CoV-2 vaccination
Subject is in one or more cohorts prioritised for vaccination
1240631000000102 Did not attend SARS-CoV-2 vaccination
Subject did not attend a scheduled appointment where they were due to receive a vaccine dose.
New entries into individual patient records should NEVER use this code: they should instead be expressed only using one of its child codes stating exactly which dose of the primary immunisation schedule had been missed.
This code has value mainly only when constructing queries to retrieve patients who have missed either dose.
1324831000000104 Did not attend for first dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine
Subject did not attend a scheduled appointment where they were due to receive the first vaccine dose (or the only dose of a single dose schedule vaccine)
1324841000000108 Did not attend for second dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine
Subject did not attend a scheduled appointment where they were due to receive the second vaccine dose
1324661000000105 Adverse reaction to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine
1324711000000102 Allergy to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccineSubject experienced some kind of adverse or allergic reaction to at least one vaccine dose.
PROCEDURE
1324671000000103 Immunisation course to achieve immunity against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)
The idea of a course of therapy intended to induce an immunity to SARS-CoV-2 infection.
This code exists mainly as a technical byproduct of creating the more specific codes (below) by which the stages of a course of treatment to immunise an individual patient can be recorded.
When recorded on its own and “as is”, this code in fact indicates that such a course was completed on that record date; this code must therefore NOT be used to record when such a course has merely started.
An immunisation course will comprise one or more vaccine dose administration events, to be coded as:1324681000000101 Administration of first dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine The subject was given the first dose of a vaccine against SARS-CoV-2 on the date recorded.
This includes the administration of the only dose of a single dose schedule vaccine (need for a subsequent dose will be informed by inspecting the record of the specific vaccine used).
1324691000000104 Administration of second dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine The subject was given the second dose of a vaccine against SARS-CoV-2 on the date recorded
SITUATION WITH EXPLICIT CONTEXT
1324731000000105 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course not indicated
The subject has no clinical indication for commencing a primary immunisation schedule against SARS-CoV-2
e.g. because they are not at (sufficient) risk.
Different from saying that only one or other dose is not indicated, for which other codes exist.
The course may be indicated at the start, but at some later point in time one of its doses is not.
Conversely, however, if the course is not indicated at the outset then by implication none of its doses are either – though it is usually considered redundant to record both that the course as a whole is not indicated and also separately that neither dose is.
1324761000000100 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course contraindicated
The entire primary immunisation schedule was not started because of e.g. Immunosuppression or other comorbidity.
Although usually permanent, such contraindications may be only temporary, and so the subject is not necessarily permanently excluded from all future enrolment in a course of vaccination.
By contrast, contraindication to a dose (see below) is more likely to be only temporary .. but a more permanent contraindication to completing the schedule is also not excluded.
Operationally, the presence of this code in the EPR as an active problem implies that no future vaccine doses should be given, at least not without careful clinical scrutiny of the recordNote that other codes also carry this or a similar implication.
See also the ‘vaccine dose contraindicated’ codes below.
1324811000000107 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course declined
The subject declined an offer to begin the primary immunisation schedule against SARS-CoV-2, and so was never invited to receive even the first dose
Different from declining individual dosing events, for which separate codes exist.A subject may agree to being immunised, decline the first dose event due to temporary illness, be rescheduled and then go on to complete the course as planned
1324851000000106 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course started
The subject accepted an offer to begin the primary immunisation schedule against SARS-CoV-2, and either has been or will be invited to receive at least the first dose
1324821000000101 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course not done
The patient has a valid indication and did not decline vaccination, but the vaccination course was never started for some other reason (e.g. policy change)
Different from “abandoned” (see below), which implies that the course WAS started
1324861000000109 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course abandoned
A primary immunisation course was started, but either zero or only the first dose was ever actually given before the attempt was permanently abandoned. No further doses will be given.
Valid reasons for recording “abandoned” could include e.g. that the patient has unfortunately already contracted COVID-19 or developed a new contraindicaiton; the patient withdraws consent to proceed; the vaccine product has to be withdrawn from the market
- If a new contraindication emerges, this should always be recorded as at least a contraindication code.
1240651000000109 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination declined
The subject declined to receive at least one vaccine dose
Technically different from contraindicated but note that the reason a subject may decline an individual dose could include that they currently feel unwell, and the underlying suspected condition causing that illness may also be a contraindication.
More common reasons could include e.g. that the appointment slot has become inconvenient or impractical for them to access, or that a child subject or needle phobic adult became too distressed to receive it
New entries into individual patient records should however ideally not be made using this code but instead only using one of its child codes that specify which vaccine dose was declined.
This code has value mainly only when constructing queries to retrieve patients for whom either dose was ever specifically declined
1324741000000101 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination first dose declined
The subject declined to receive the first vaccine dose (or the only dose of a single dose schedule vaccine), on the record date
Where the vaccinator declines to administer the vaccine to the subject for any reason (e.g physical aggression from an elderly and confused subject), a different “not given” code should be used
1324751000000103 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination second dose declined
The subject declined to receive the second vaccine dose, on the record date
Where the vaccinator declines to administer the vaccine to the subject for any reason (e.g physical aggression from an elderly and confused subject), a different “not given” code should be used
1324771000000107 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination dose not given
Administration of at least one vaccine dose could not be performed
New entries into individual patient records should however ideally not be made using this code but instead only using one of its child codes that specify which vaccine dose was declined.
This code has value mainly only when constructing queries to retrieve patients for whom either dose could not be given for any reason
1324781000000109 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination first dose not given
A scheduled administration of the first vaccine dose (or the only dose of a single dose schedule vaccine) could not be performed, on the record date, for any reason EXCEPT those separately codeable (did not attend, contraindicated, declined)
Reasons could include e.g. lack of vaccine dose supply; aggressive behaviour toward the vaccinator by the subject
1324791000000106 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination second dose not given
A scheduled administration of the second vaccine dose could not be performed, on the record date, for any reason EXCEPT those separately codeable (did not attend, contraindicated, declined)
Reasons could include e.g. lack of vaccine dose supply; aggressive behaviour toward the vaccinator by the subject
PHARMACEUTICAL / BIOLOGIC PRODUCT
39115611000001103 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd)
39114911000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca)
39230211000001104 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials (Janssen-Cilag Ltd)
39326911000001101 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5mL dose dispersion for injection multidose vials (Moderna, Inc)
39373511000001104 COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd)
39473011000001103 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH)
The above codes correspond to the actual manufactured vaccine products (AMP) and should be used to share information concerning vaccine administration (i.e. to represent which vaccine was given to an individual patient). They must not be confused with other related codes (see below) corresponding to manufacturer packs containing more than one vaccine dose (VMPP and AMPP below) or to the abstract notion of a manufacturer-agnostic formulation (VMP).
However, the GTIN (‘barcode’), when available, will be linked to the AMPP code and therefore AMPPs will need to be recognised for scanned input of product. Using relationships provided within dm+d natively and in its SNOMEDised derivative, AMPP codes obtained by scanning should then be coerced into a related AMP code (as above) in order for the AMP code only to be communicated as the record of the vaccine product actually administered to an individual patient.
VMP: 39116111000001100 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials
VMPP: 39115311000001108 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials 6 doseVMPP: 39214411000001100 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials 1170 dose – 195 x 6 dose vials
AMPP: 39115711000001107 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd) 6 dose
AMPP: 39214511000001101 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd) 1170 dose – 195 x 6 dose vials GTIN: 00359267100023
VMP: 39116211000001106 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials
VMPP: 39114711000001108 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 8 dose
VMPP: 39114811000001100 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 10 doseVMPP: 39301011000001100 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 80 dose 10 x 8 dose vials
VMPP: 39301111000001104 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 100 dose 10 x 10 dose vialsAMPP: 39115011000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 8 dose
AMPP: 39115111000001106 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 10 doseAMPP: 39301211000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 80 dose 10 x 8 dose vials GTIN: 05000456063876
AMPP: 39301311000001102 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 100 dose 10 x 10 dose vials GTIN: 05000456063821VMP: 39233911000001100 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials
VMPP: 39230011000001109 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials 5 dose
VMPP: 39230111000001105 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials 50 dose
AMPP: 39230311000001107 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials (Janssen-Cilag Ltd) 5 dose
AMPP: 39230411000001100 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials (Janssen-Cilag Ltd) 50 doseVMP: 39326811000001106 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5mL dose dispersion for injection multidose vials
VMPP: 39375311000001106 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials 10 doseVMPP: 39326611000001107 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials 100 dose 10 x 10 dose vials
AMPP: 39375411000001104 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials (Moderna, Inc) 10 dose
AMPP: 39327011000001102 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials (Moderna, Inc) 100 dose 10 x 10 dose vials GTIN: 30380777700688
VMP: 39375211000001103 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials
VMPP: 39373011000001107 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials 10 doseVMPP: 39373111000001108 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials 100 dose 10 x 10 dose vials
AMPP: 39374411000001100 COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd) 10 doseAMPP: 39374711000001106 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd) 100 dose 10 x 10 dose vials GTIN: 09120040710330
VMP: 39330711000001103 Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials
VMPP: 39472811000001101 Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials 10 dose
VMPP: 39472911000001106 Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials 100 dose 10 x 10 dose vials
AMPP: 39473111000001102 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH) 10 dose
AMPP: 39473211000001108 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH) 100 dose 10 x 10 dose vials GTIN: 00380631100103
UNUSED
The codes below, although both published and still active in SNOMED CT, are considered now unlikely to be used within the UK:
1240781000000106 SARS-CoV-2 vaccination invitation short message service text message sent
This code is expected to be supplanted within the national immunisation system by codes internal to that system.
It is believed that this level of administrative detail does not need sharing into the wider clinical systems
1240701000000101 SARS-CoV-2 vaccine not available
This code is expected to be supplanted within the national immunisation system by codes internal to that system.
It is believed that this level of administrative detail does not need sharing into the wider clinical systems.
If a vaccine dose could not be administered because no dose was available, this may be messaged to the wider clinical system using one of the “dose not given” codes above.
WITHDRAWN
The codes below were added earlier in 2020 to the UK SNOMED Edition but are now made inactive and should not be used.
1240491000000103 Severe acute respiratory syndrome coronavirus 2 vaccination (procedure)
1240661000000107 Severe acute respiratory syndrome coronavirus 2 vaccination contraindicated (situation)
1240651000000109 Severe acute respiratory syndrome coronavirus 2 vaccination declined (situation)
1240681000000103 Severe acute respiratory syndrome coronavirus 2 vaccination not done (situation)
1240671000000100 Severe acute respiratory syndrome coronavirus 2 vaccination not indicated (situation)END.
Kind regards,
Terminology and Classifications Delivery Service
By Claire Fennell 2 years ago
-
Delay to 31.0.0 SNOMED CT UK Edition Release
Published: October 2020
Dear colleague,
Please note that due to a service disruption there has been a delay to the production of the 31.0.0 SNOMED CT UK Edition.
This will delay the release of the:
- SNOMED CT International Edition
- SNOMED CT UK Clinical Extension
- SNOMED CT UK Drug Extension
The 31.0.0 SNOMED CT UK Edition will be published on Wednesday 11 November 2020, instead of its expected release date of Wednesday 04 November 2020.
NHS Digital is sorry for any inconvenience that this will cause you.
Kind regards
Terminology & Classifications Delivery Service
By Katy Park 2 years ago
-
Consultation on SNOMED CT Release Frequency and Changes to Subfolder Structure
Published: September 2020
Dear colleague,
The uncertainty surrounding COVID-19 has necessitated the need for a rapid and responsive service beyond what our regular six-monthly release cycle can offer. We are running a consultation on our SNOMED CT UK Clinical Edition frequency for 2020 and beyond.
Release Frequency
We therefore propose a permanent shift to a minimum of seven scheduled releases of the UK Clinical Edition annually, made up of:
- Two major releases annually in September/October and March, to update SNOMED CT UK Edition with the latest International Edition releases
- Five minor releases of SNOMED CT UK Clinical Edition compromising of only incremental updates and other additions to UK Clinical Edition content
- Unlike the 2020 “microreleases”, future minor releases will not be restricted to urgent COVID-19 related content only. Instead, all UK-specific “business as usual” content that was previously released only in two batches (April and October) will become distributed more or less equally across the full set of seven or more annual releases, both major and minor.
- The SNOMED CT Drug Edition four-weekly release cycle will remain unchanged: each release of SNOMED CT UK Clinical Edition will always co-occur with a scheduled release of the Drug Edition.
Should the clinical need arise, this typical annual schedule of seven releases may exceptionally be supplemented by one or more additional unscheduled emergency releases; these would however also occur on the same date as the next scheduled release of the UK Drug Edition. The proposed continuing release schedule is therefore fundamentally based on the underlying 4-weekly cycle time of the UK Drug Edition:
Planned changes to the SNOMED CT UK Edition release subfolder structure
From the first scheduled release in 2021 (27 January 2021), all PRODUCTION releases of UK Clinical and Drug will adopt the BETA encoding structure. All releases of both UK Clinical and UK Drug Editions will continue to be published in parallel in both the older LEGACY encoding as well as in the new PRODUCTION encoding, but only until the end of March 2021 after which the LEGACY encoding will be permanently withdrawn.
For a more detailed explanation of the motivations for the BETA bundling, see the webinar recording at this location. Detailed information is also provided in the UK Clinical Edition SNOMED CT Technical overview document, section 2.4.1 and 2.4.2.
Throughout the remainder of 2020, PRODUCTION releases will remain as before but with the same content always co-published on TRUD in BETA format, as Test Releases: Clinical Edition and Drug Extension 29.3.0, RF2, BETA: Full, Snapshot & Delta.
Kind regards
Terminology and Classifications Delivery Service
By Katy Park 2 years ago
About
Browse through our blog articles or select the relevant categories below to find the information you're looking for.
Tags
Articles
2023
- Jan Feb Mar Apr May
2022
- Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021
- Jan Feb Mar Apr Jun Sep Oct Nov Dec
2020
- Jan Feb Mar Apr May Jun Aug Sep Oct Nov Dec
2019
- Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018
- Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2017
- Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec